J L Gu, C H Zhong, M L Chen, L F Kuang, X Z Li, B H Huang, J R Liu, J Li
{"title":"[调查自体干细胞移植后长期存活的多发性骨髓瘤患者的免疫概况]。","authors":"J L Gu, C H Zhong, M L Chen, L F Kuang, X Z Li, B H Huang, J R Liu, J Li","doi":"10.3760/cma.j.cn112138-20230906-00112","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To identify the characteristics of the bone marrow immune microenvironment associated with long-term survival in multiple myeloma (MM) patients. <b>Methods:</b> In the follow-up cohort of patients with newly diagnosed MM and who received \"novel agent induction therapy and subsequent autologous stem cell transplantation and immunomodulator maintenance therapy\" in the First Affiliated Hospital of Sun Yat-sen University, a cross-sectional study was carried out between August 2019 and May 2020. Using NanoString technology, the RNA expression of 770 bone marrow immune-related markers was compared between 16 patients who had progression-free survival ≥5 years and 5 patients with progressive disease. Among the 16 patients who achieved long-term survival, 9 achieved persistent minimal residual disease (MRD) negative while the other 7 had persistent positive MRD. The functional scores of each kind of immune cells were calculated based on the expression level of characteristic genes, so as to indirectly obtained the proportion of each immune cell subset. The Mann-Whitney <i>U</i> test and the Kruskal Wallis test were used for statistical analysis. <b>Results:</b> The proportion of neutrophils was significantly higher in long-surviving MM patients than in patients with progressive disease [functional scores, 13.61 (13.33, 14.25) vs. 12.93 (12.58, 13.38); <i>Z</i>=2.31, <i>P</i>=0.021]. Among long-surviving patients, those who were MRD-positive had a significantly greater number of mast cells compared with those who were MRD-negative [functional scores, 7.09 (6.49, 8.57) vs. 6.03 (5.18, 6.69); <i>H</i>=2.18, <i>P</i>=0.029]. Compared with patients with progressive disease, four genes (CTSG, IFIT2, S100B, and CHIT1) were significantly downregulated and six (C4B, TNFRSF17, CD70, IRF4, C2, and GAGE1) were upregulated in long-surviving patients. Among long-surviving patients, only gene CMA1 was significantly upgraded, 10 genes (ISG15, OAS3, MX1, IFIT2, DDX58, SIGLEC1, CXCL10, IL1RN, SERPING and TNFSF10) were significantly downregulated in the MRD-positive group compared with that in the MRD-negative group, the first 5 of which are related to the interferon response pathway. <b>Conclusions:</b> The increased neutrophil and mast cell numbers may be related to long-term survival in MM. Interferon signaling activation may be a key bone marrow immune profiling feature for MRD-negative, long-surviving patients with MM.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Investigation of the immune profile of multiple myeloma patients achieving long-term survival after autologous stem cell transplantation].\",\"authors\":\"J L Gu, C H Zhong, M L Chen, L F Kuang, X Z Li, B H Huang, J R Liu, J Li\",\"doi\":\"10.3760/cma.j.cn112138-20230906-00112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To identify the characteristics of the bone marrow immune microenvironment associated with long-term survival in multiple myeloma (MM) patients. <b>Methods:</b> In the follow-up cohort of patients with newly diagnosed MM and who received \\\"novel agent induction therapy and subsequent autologous stem cell transplantation and immunomodulator maintenance therapy\\\" in the First Affiliated Hospital of Sun Yat-sen University, a cross-sectional study was carried out between August 2019 and May 2020. Using NanoString technology, the RNA expression of 770 bone marrow immune-related markers was compared between 16 patients who had progression-free survival ≥5 years and 5 patients with progressive disease. Among the 16 patients who achieved long-term survival, 9 achieved persistent minimal residual disease (MRD) negative while the other 7 had persistent positive MRD. The functional scores of each kind of immune cells were calculated based on the expression level of characteristic genes, so as to indirectly obtained the proportion of each immune cell subset. The Mann-Whitney <i>U</i> test and the Kruskal Wallis test were used for statistical analysis. <b>Results:</b> The proportion of neutrophils was significantly higher in long-surviving MM patients than in patients with progressive disease [functional scores, 13.61 (13.33, 14.25) vs. 12.93 (12.58, 13.38); <i>Z</i>=2.31, <i>P</i>=0.021]. Among long-surviving patients, those who were MRD-positive had a significantly greater number of mast cells compared with those who were MRD-negative [functional scores, 7.09 (6.49, 8.57) vs. 6.03 (5.18, 6.69); <i>H</i>=2.18, <i>P</i>=0.029]. Compared with patients with progressive disease, four genes (CTSG, IFIT2, S100B, and CHIT1) were significantly downregulated and six (C4B, TNFRSF17, CD70, IRF4, C2, and GAGE1) were upregulated in long-surviving patients. Among long-surviving patients, only gene CMA1 was significantly upgraded, 10 genes (ISG15, OAS3, MX1, IFIT2, DDX58, SIGLEC1, CXCL10, IL1RN, SERPING and TNFSF10) were significantly downregulated in the MRD-positive group compared with that in the MRD-negative group, the first 5 of which are related to the interferon response pathway. <b>Conclusions:</b> The increased neutrophil and mast cell numbers may be related to long-term survival in MM. Interferon signaling activation may be a key bone marrow immune profiling feature for MRD-negative, long-surviving patients with MM.</p>\",\"PeriodicalId\":68309,\"journal\":{\"name\":\"中华内科杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华内科杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112138-20230906-00112\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华内科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112138-20230906-00112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:确定与多发性骨髓瘤(MM)患者长期生存相关的骨髓免疫微环境特征:确定与多发性骨髓瘤(MM)患者长期生存相关的骨髓免疫微环境特征。方法在2019年8月至2020年5月期间,对中山大学附属第一医院接受 "新药诱导治疗及随后的自体干细胞移植和免疫调节剂维持治疗 "的新诊断MM患者进行了一项横断面研究。利用NanoString技术,比较了16名无进展生存期≥5年的患者和5名疾病进展期患者的770个骨髓免疫相关标志物的RNA表达。在 16 名获得长期生存的患者中,9 人的最小残留病灶(MRD)持续阴性,另外 7 人的 MRD 持续阳性。根据特征基因的表达水平计算各类免疫细胞的功能评分,从而间接得出各类免疫细胞亚群所占的比例。统计分析采用 Mann-Whitney U 检验和 Kruskal Wallis 检验。结果长期存活的 MM 患者的中性粒细胞比例明显高于疾病进展期患者[功能评分,13.61 (13.33, 14.25) vs. 12.93 (12.58, 13.38);Z=2.31,P=0.021]。在长期存活的患者中,MRD阳性患者的肥大细胞数量明显多于MRD阴性患者[功能评分,7.09(6.49,8.57) vs. 6.03(5.18,6.69);H=2.18,P=0.029]。与进展期患者相比,长存活期患者的四个基因(CTSG、IFIT2、S100B 和 CHIT1)明显下调,六个基因(C4B、TNFRSF17、CD70、IRF4、C2 和 GAGE1)上调。与 MRD 阴性组相比,MRD 阳性组中只有 CMA1 基因明显上调,10 个基因(ISG15、OAS3、MX1、IFIT2、DDX58、SIGLEC1、CXCL10、IL1RN、SERPING 和 TNFSF10)明显下调,其中前 5 个基因与干扰素反应途径有关。结论中性粒细胞和肥大细胞数量的增加可能与 MM 的长期生存有关。干扰素信号激活可能是MRD阴性、长期存活的MM患者骨髓免疫图谱的一个关键特征。
[Investigation of the immune profile of multiple myeloma patients achieving long-term survival after autologous stem cell transplantation].
Objective: To identify the characteristics of the bone marrow immune microenvironment associated with long-term survival in multiple myeloma (MM) patients. Methods: In the follow-up cohort of patients with newly diagnosed MM and who received "novel agent induction therapy and subsequent autologous stem cell transplantation and immunomodulator maintenance therapy" in the First Affiliated Hospital of Sun Yat-sen University, a cross-sectional study was carried out between August 2019 and May 2020. Using NanoString technology, the RNA expression of 770 bone marrow immune-related markers was compared between 16 patients who had progression-free survival ≥5 years and 5 patients with progressive disease. Among the 16 patients who achieved long-term survival, 9 achieved persistent minimal residual disease (MRD) negative while the other 7 had persistent positive MRD. The functional scores of each kind of immune cells were calculated based on the expression level of characteristic genes, so as to indirectly obtained the proportion of each immune cell subset. The Mann-Whitney U test and the Kruskal Wallis test were used for statistical analysis. Results: The proportion of neutrophils was significantly higher in long-surviving MM patients than in patients with progressive disease [functional scores, 13.61 (13.33, 14.25) vs. 12.93 (12.58, 13.38); Z=2.31, P=0.021]. Among long-surviving patients, those who were MRD-positive had a significantly greater number of mast cells compared with those who were MRD-negative [functional scores, 7.09 (6.49, 8.57) vs. 6.03 (5.18, 6.69); H=2.18, P=0.029]. Compared with patients with progressive disease, four genes (CTSG, IFIT2, S100B, and CHIT1) were significantly downregulated and six (C4B, TNFRSF17, CD70, IRF4, C2, and GAGE1) were upregulated in long-surviving patients. Among long-surviving patients, only gene CMA1 was significantly upgraded, 10 genes (ISG15, OAS3, MX1, IFIT2, DDX58, SIGLEC1, CXCL10, IL1RN, SERPING and TNFSF10) were significantly downregulated in the MRD-positive group compared with that in the MRD-negative group, the first 5 of which are related to the interferon response pathway. Conclusions: The increased neutrophil and mast cell numbers may be related to long-term survival in MM. Interferon signaling activation may be a key bone marrow immune profiling feature for MRD-negative, long-surviving patients with MM.